# SKB105 for Injection in Advanced Solid Tumors

Source: https://onco.cc/trials/nct07380386/  
OnCo record `nct07380386` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SKB105 for injection Monotherapy in advanced solid tumours, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.

## Summary

SKB105 for Injection in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07380386 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 256 participants planned, started 2026-03-05 and due to reach its primary completion in 2029-12-31. Interventions recorded: SKB105 for injection Monotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07380386
- Phase: 1/2
- Setting: A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SKB105 for Injection in Participants With Advanced Solid Tumors
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Enrolled: 256

## Sources

- ClinicalTrials.gov NCT07380386: https://clinicaltrials.gov/study/NCT07380386

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)
- drugs: [SKB105](https://onco.cc/drugs/skb105/)

---
JSON: https://onco.cc/api/v1/entities/nct07380386.json